Evidence of a clonal T-cell immune response in patients with breast cancer (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Evidence of a clonal T-cell immune response in patients with breast cancer (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 14:A108 1995. Unique Identifier : AIDSLINE ICDB/95613263
Ito K; Chang MY; Vinciguerra V; Silver J; Fetten JV; Don Monti Division of Medical Oncology, North Shore Univ. Hosp.,; Manhasset, NY 11030

Abstract: Evidence is accumulating that an immune response directed against tumor cells develops in patients with breast cancer. The degree to which this participates in the control of disease is unknown, but several intriguing findings are known: (1) Two unique antigens are present on breast cancer cells which are absent in their nonmalignant counterpart; (2) Cytotoxic T-cell activity has been demonstrated in lymphocytes from patients which are able to recognize and kill breast cancer cells. We performed T-cell receptor analysis on lymphocytes derived from draining lymph node specimens and peripheral blood samples of breast cancer patients. We observed that the patterns of TCR V beta gene usage in draining lymph nodes of breast cancer patients is different from that of peripheral blood lymphocytes. In addition, using a 2-step PCR method to analyze CDR 3 length, oligoclonality was observed in specific V beta gene families in the CD8+ cells from draining lymph nodes of 3/7 patients. This clonal predominance persisted in vitro by co-cultivation with breast cancer cell lines, but disappears by stimulating with nonbreast cancer cell lines. Interestingly, these T-cell clones are present only in lymphocytes derived from draining lymph nodes and not in peripheral blood lymphocytes. Since the CDR 3 region of the TCR constitutes the specific site of interaction with the antigen/MHC complex, the existence of clonal dominance in the CD8+ compartment of draining lymph nodes from patients suggests the development of a specific T-cell response to breast cancer.

Keywords: Breast Neoplasms/GENETICS/*IMMUNOLOGY Cell Line Clonal Anergy Cytotoxicity, Immunologic CD8-Positive T-Lymphocytes/IMMUNOLOGY Human Lymph Nodes/IMMUNOLOGY Polymerase Chain Reaction/METHODS Receptor-CD3 Complex, Antigen, T-Cell/BIOSYNTHESIS/GENETICS Receptors, Antigen, T-Cell/ANALYSIS Receptors, Antigen, T-Cell, alpha-beta/BIOSYNTHESIS/GENETICS T-Lymphocytes/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/IMMUNOLOGY Tumor Cells, Cultured ABSTRACT

951130
M95B0946

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .